BioCentury | Jan 12, 2018
Company News

Celgene reports preliminary earnings, adds JAK inhibitor with Impact deal

...colorectal cancer. Hood was director of research at TargeGen Inc., which originally developed fedratinib. Sanofi acquired TargeGen...
...Celgene Corp. (NASDAQ:CELG), Summit, N.J. Impact Biomedicines Inc., San Diego, Calif. Business: Hematology Jennie Walters fedratinib lenalidomide Revlimid Celgene Corp. Impact Biomedicines TargeGen Inc. JAK-2 Janus...
BioCentury | Jan 8, 2018
Company News

Celgene reports preliminary earnings, adds JAK inhibitor with Impact deal

...colorectal cancer. Hood was director of research at TargeGen Inc., which originally developed fedratinib. Sanofi acquired TargeGen...
BioCentury | Jan 16, 2015
Financial News

CTI raises C$134M toward second fund

...return if all milestones are reached. Other investments include Medicago Inc. (Quebec City, Quebec) and TargeGen Inc....
BioCentury | Nov 25, 2013
Clinical News

Fedratinib: Development discontinued

...from FDA for the trial. The pharma gained the product through its 2010 acquisition of TargeGen Inc....
BioCentury | Nov 19, 2013
Company News

Sanofi discontinues JAK-2 inhibitor in development for MF

...of fedratinib outweighed its benefit. The pharma gained the product through its 2010 acquisition of TargeGen Inc....
BioCentury | May 20, 2013
Clinical News

SAR302503: Phase III data

...on a potential time frame. Sanofi, which gained the product through its 2010 acquisition of TargeGen Inc....
BioCentury | May 18, 2013
Top Story

Sanofi's SAR302503 meets in myelofibrosis

...pharma, which gained the selective oral Janus kinase-2 (JAK-2) inhibitor through its 2010 acquisition of TargeGen Inc....
BioCentury | Apr 29, 2013
Strategy

Zerhouni's progress report

...are available online .(A) From Genzyme acquisition; (B) Antisense therapy; (C) From 2010 acquisition of TargeGen Inc....
BioCentury | Feb 11, 2013
Finance

CTI sees green

...two spectacular exits," Tilley said. The first came in 2010 when Sanofi (Euronext:SAN; NYSE:SNY) bought TargeGen Inc....
...could bring the return to 3X. This year, Sanofi will report Phase III data for TargeGen's...
BioCentury | Dec 10, 2012
Clinical News

SAR302503: Phase II data

...of Hematology meeting in Atlanta. Sanofi, which gained the product through its 2010 acquisition of TargeGen Inc....
Items per page:
1 - 10 of 61
BioCentury | Jan 12, 2018
Company News

Celgene reports preliminary earnings, adds JAK inhibitor with Impact deal

...colorectal cancer. Hood was director of research at TargeGen Inc., which originally developed fedratinib. Sanofi acquired TargeGen...
...Celgene Corp. (NASDAQ:CELG), Summit, N.J. Impact Biomedicines Inc., San Diego, Calif. Business: Hematology Jennie Walters fedratinib lenalidomide Revlimid Celgene Corp. Impact Biomedicines TargeGen Inc. JAK-2 Janus...
BioCentury | Jan 8, 2018
Company News

Celgene reports preliminary earnings, adds JAK inhibitor with Impact deal

...colorectal cancer. Hood was director of research at TargeGen Inc., which originally developed fedratinib. Sanofi acquired TargeGen...
BioCentury | Jan 16, 2015
Financial News

CTI raises C$134M toward second fund

...return if all milestones are reached. Other investments include Medicago Inc. (Quebec City, Quebec) and TargeGen Inc....
BioCentury | Nov 25, 2013
Clinical News

Fedratinib: Development discontinued

...from FDA for the trial. The pharma gained the product through its 2010 acquisition of TargeGen Inc....
BioCentury | Nov 19, 2013
Company News

Sanofi discontinues JAK-2 inhibitor in development for MF

...of fedratinib outweighed its benefit. The pharma gained the product through its 2010 acquisition of TargeGen Inc....
BioCentury | May 20, 2013
Clinical News

SAR302503: Phase III data

...on a potential time frame. Sanofi, which gained the product through its 2010 acquisition of TargeGen Inc....
BioCentury | May 18, 2013
Top Story

Sanofi's SAR302503 meets in myelofibrosis

...pharma, which gained the selective oral Janus kinase-2 (JAK-2) inhibitor through its 2010 acquisition of TargeGen Inc....
BioCentury | Apr 29, 2013
Strategy

Zerhouni's progress report

...are available online .(A) From Genzyme acquisition; (B) Antisense therapy; (C) From 2010 acquisition of TargeGen Inc....
BioCentury | Feb 11, 2013
Finance

CTI sees green

...two spectacular exits," Tilley said. The first came in 2010 when Sanofi (Euronext:SAN; NYSE:SNY) bought TargeGen Inc....
...could bring the return to 3X. This year, Sanofi will report Phase III data for TargeGen's...
BioCentury | Dec 10, 2012
Clinical News

SAR302503: Phase II data

...of Hematology meeting in Atlanta. Sanofi, which gained the product through its 2010 acquisition of TargeGen Inc....
Items per page:
1 - 10 of 61